J&J Medical Connect
CAPLYTA®

(lumateperone)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

CAPLYTA – Adverse Event – Serotonin Syndrome

Last Updated: 10/28/2026

SUMMARY

  • There were no reports of serotonin syndrome adverse events in CAPLYTA clinical trials across all indications (adjunctive major depressive disorder [MDD], bipolar I or II disorder, and schizophrenia).
  • Sun et al (2025)1 conducted an analysis of postmarketing safety data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database from the fourth quarter of 2019 to the fourth quarter of 2023 to evaluate the adverse events of CAPLYTA in patients with schizophrenia. In this study, 12 cases of serotonin syndrome were reported.

PRODUCT LABELING

Clinically Important Drug Interactions with CAPLYTA

Increased monitoring for serotonin reuptake inhibitors (SRIs)-associated adverse reactions is recommended.2 

Although no clinically significant drug interactions with adjunctive selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (SSRIs/SNRIs) in MDD were observed in CAPLYTA clinical trials, CAPLYTA’s moderate serotonin transporter (SERT) activity may increase the risk of SRI-associated adverse reactions (e.g., serotonin syndrome, hyponatremia).2 

clinical data

There were no reports of serotonin syndrome adverse events in CAPLYTA clinical trials across all indications (adjunctive MDD, bipolar I or II disorder, and schizophrenia).

postmarketing safety data

FDA Adverse Event Reporting System (FAERS)

Sun et al (2025)1 conducted an analysis using the FAERS database (fourth quarter of 2019 to the fourth quarter of 2023) to evaluate the adverse events of CAPLYTA in patients with schizophrenia. Overall, 12 cases of serotonin syndrome were reported (reporting odds ratio [ROR] 8.87, 95% confidence interval [CI], 5.03-15.64).

FAERS is a voluntary reporting system that has certain limitations, and not all adverse events related to CAPLYTA are reported to the FDA. Interpretation of the FAERS findings is limited by the higher proportion of consumer reports for CAPLYTA, which may introduce uncertainty due to limited healthcare expertise, and by the inherent limitations of spontaneous reporting and data-mining methods, which cannot replace expert review. Relying solely on FAERS data cannot determine a causal relationship between drug use and adverse events.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 21 October 2026.

References

1 Sun S, Zhang Y, Wu H, et al. Analysis of lumateperone data for patients with schizophrenia using related adverse events from the FDA adverse reporting system. Expert Opin Drug Saf. 2025;24(9):1083-1093.  
2 CAPLYTA (lumateperone) [Prescribing Information]. Titusville, NJ: Intra-Cellular Therapies, Inc; https://www.intracellulartherapies.com/docs/caplyta_pi.pdf   

Would you like to clear and leave your conversation? Message history will be lost.